SIGHT — Gensight Biologics SA Balance Sheet
0.000.00%
- €13.76m
- €32.51m
- €1.50m
Annual balance sheet for Gensight Biologics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 37.9 | 44.3 | 10.6 | 2.13 | 2.46 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.91 | 4.63 | 3.63 | 2.44 | 2 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 43.8 | 53.4 | 22.9 | 6.53 | 5.34 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.15 | 2.55 | 2.27 | 2.02 | 0.933 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 47.4 | 56.6 | 25.9 | 9.13 | 10.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 17.1 | 22.2 | 14.6 | 25.3 | 22.6 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 35.6 | 40.7 | 41.2 | 39.8 | 37.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 11.7 | 16 | -15.3 | -30.7 | -26.9 |
| Total Liabilities & Shareholders' Equity | 47.4 | 56.6 | 25.9 | 9.13 | 10.8 |
| Total Common Shares Outstanding |